NRX Pharmaceuticals (NRXP) Tax Provisions (2018 - 2024)

NRX Pharmaceuticals' (NRXP) quarterly Tax Provisions came in at $3000.0 in Q3 2024, up 156.01% on a QoQ basis from -$5356.0 in Q4 2020.

NRX Pharmaceuticals (NRXP) Tax Provisions (2018 - 2024) Analysis & Trends

NRX Pharmaceuticals (NRXP) has 4 years of Tax Provisions data on file, last reported at $3000.0 in Q3 2024.

On a quarterly basis, Tax Provisions changed N/A year-over-year to $3000.0 in Q3 2024; TTM through Sep 2025 was $3000.0, a 0.0% change from a year earlier, with the FY2020 full-year figure at $17841.0, down 82.57% from the prior year.
Tax Provisions for Q3 2024 stood at $3000.0, up from -$5356.0 in the prior quarter.
Over the last five years, Tax Provisions for NRXP reached as high as $72628.0 in Q1 2020 and fell as low as -$42690.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	125,146.46
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	31.86 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	188,883.60
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	221.50 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	104.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	179.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	NRX Pharmaceuticals	137.57 Mn	130.87 Mn	437,000.00	-

Download Data